Results 91 to 100 of about 14,718 (260)

A rare case of primary carcinoma of axillary accessory breast tissue. [PDF]

J Surg Case Rep, 2021
Sikdar O, Roy M, Al-Ishaq Z, Shinde V, Sircar T.   +4 more
europepmc   +1 more source

Leveraging Artificial Intelligence and Large Language Models for Cancer Immunotherapy

Advanced Science, EarlyView.
Cancer immunotherapy faces challenges in predicting treatment responses and understanding resistance mechanisms. Artificial intelligence (AI) and machine learning (ML) offer powerful solutions for cancer immunotherapy in patient stratification, biomarker discovery, treatment strategy optimization, and foundation model development.
Xinchao Wu, Mengtao Sun, Lusheng Li, Jieqiong Wang, Shibiao Wan   +4 more
wiley   +1 more source

A rare case report of left axillary fibroadenoma in a 45-year-old woman [PDF]

Majallah-i Zanān, Māmā̓ī va Nāzā̓ī-i Īrān
Introduction: Breast fibroadenoma in the axilla is a rare manifestation that consists of biphasic proliferation of fibromyxoid stroma without atypia or mitosis, with a glandular component consisting of two luminal and myoepithelial layers. In this study,
Mahsa Akbari Oryani, zahra Akhbari, Ehsan Hassanzadeh Haddad   +2 more
doaj   +1 more source

Primary carcinoma of ectopic axillary breast tissue.

, 2006
The presence of ectopic breast tissue is reported in 2-6% of the general population with most cases being located in the axillary region. Although the same pathology occurs in both eutopic and ectopic breast tissue, primary carcinoma of ectopic breast ...
Gutermuth, J;Audring, H;Voit, C;Haas, N
core   +1 more source

Correction of accessory axillary breast tissue without visible scar [PDF]

Aesthetic Surgery Journal, 2004
Various methods for correction of accessory axillary breast tissue have been proposed, including simple excision, diamond-shaped excision, a Y-V technique, and lipoplasty.We present an effective method for correction of a prominent axillary mound that combines lipoplasty with excision of accessory breast tissue along the axillary transverse line ...
openaire   +2 more sources

The Development and Pilot Clinical Study of CD147 Targeted Antagonistic Peptide Probe for Tumor Imaging

Advanced Science, EarlyView.
This study establishes [68Ga]Ga‐DOTA‐AP9 as a first‐in‐human CD147‐targeted PET tracer with favorable safety and specific tumor uptake. Tracer accumulation correlates with CD147 expression in patients, enabling noninvasive quantification of CD147‐positive malignancies.
Xiaokun Ma, Rui Guo, Dongfeng Niu, Yufei Song, Zhenyao Zhang, Xiangxi Meng, Lili Mao, Haifeng Huang, Hua Zhu, Zhi Yang, Teli Liu   +10 more
wiley   +1 more source

Determining Leukocyte Origins Using Parabiosis in the PyMT Breast Tumor Model

Bio-Protocol, 2015
Tumors develop in a complex microenvironment alongside numerous cell types that impact their survival. Immune cells make up a large proportion of these accessory cells and many are known to promote tumor progression.
Ruth Franklin, Ming Li
doaj   +1 more source

Expression of CDK7, cyclin H and MAT1 is elevated in breast cancer and is prognostic in estrogen receptor- positive breast cancer [PDF]

, 2016
PURPOSE: CDK-activation kinase (CAK) is required for the regulation of the cell-cycle and is a trimeric complex consisting of Cyclin Dependent Kinase 7 (CDK7), Cyclin H and the accessory protein, MAT1.
Patel, Hetal, Gemma C, Jerjees D, Shousha, S., Magnani, L., Buluwela, Laki, Magnani L, Gemma, C., Gomm, JJ, Magnani, L, Periyasamy, Manikandan, Jones JL, Lai, C.-F., Busonero, C, Busonero C, Shousha S, Patel N, Rakha, E. A., Smith, Sally, Shousha, S, Patel H, Gemma, C, Patel, N., Buluwela, L., Gomm, J. J., Patel, Naina, Gyorffy, Balazs, Jerjees, D., Jones, L. J., Patel, H., Steel, J, Abduljabbar R, Coombes RC, Buluwela L, Ali, S, Periyasamy, M., Smith, S., Remenyi, Judit, Ellis, IO, Jones, J Louise, Coombes, RC, Ellis, I. O., Fuller-Pace, FV, Ali, S., Abduljabbar, R, Remenyi J, Harrod, A, Buluwela, L, Lai CF, Gomm, Jennifer J, Magnani, Luca, Fuller-Pace FV, Shousha, Sami, Rakha, Emad A, Ali, Simak, Jerjees, D, Steel J, Coombes, R Charles, Remenyi, J, Abduljabbar, Rezvan, Periyasamy M, Busonero, Claudia, Gomm JJ, Harrod, A., Busonero, C., Ellis, Ian O, Smith, S, Jones, JL, Abduljabbar, R., Gyorffy, B., Fuller-Pace, F., Jerjees, Dena, Harrod A, Steel, Jenny, Rakha, EA, Periyasamy, M, Harrod, Alison, Steel, J. H., Patel, H, Gyorffy, B, Lai, Chun Fui, Ellis IO, Lai, CF, Remenyi, J., Smith S, Fuller-Pace, Frances V, Ali S, Coombes, R. C., Gemma, Carolina, Patel, N, Rakha EA   +90 more
core   +1 more source

Nanomedicine Meets Immunotherapy: Advancing Adoptive Cell Therapy with Nanoparticles in the Treatment of Cancer with Sustainability Perspectives

Advanced Science, EarlyView.
This review surveys nanoparticle‐based strategies to enhance adoptive cell therapy, particularly CAR‐T cell approaches, in solid tumor treatment. It describes how nanoparticles can improve tumor immunogenicity and T‐cell infiltration while reducing toxicity, and how they enable in vivo CAR‐T cell generation.
Erica Frostegård, Tatiana Bobrova, Amalie Leinebø, Thibault Leray, Shayamita Ghosh, Lorena García‐Hevia, Chiara Puccinelli, Lorenzo Riccio, Jacopo Sorani, Davide Bonifazi, Julien Caumartin, Emmanuel Donnadieu, Florence Gazeau, Roland Hischier, Else Marit Inderberg, Mónica L. Fanarraga, Maria Loustau, Bernd Nowack, Sébastien Wälchli, Cécilia Ménard‐Moyon   +19 more
wiley   +1 more source

Early Detection and Inhibition of Post‐Surgical Cancer Recurrence by Synthetic Extracellular Vesicles

Advanced Science, EarlyView.
An implantable hydrogel is designed to hold gene transfection agents engineered to turn early recurrent tumor cells into generators of synthetic EVs. These synthetic EVs can express engineered miR‐26a (E‐miR‐26a) for highly sensitive detection and PD‐1 (a PD‐L1‐blocking agent) for therapeutic intervention, thereby enabling early detection and ...
Junli Zhang, Wenjia Chang, Ruolin Hu, Peiyan Su, Qin Zhou, Yanan Li, Zhenzhong Zhang, Kaixiang Zhang   +7 more
wiley   +1 more source